Biohaven Ltd (BHVN)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

$11.14

Buy

$11.55

arrow-up$0.09 (+0.79%)

Prices updated at 13 Dec 2025, 00:48 EST
| Prices minimum 15 mins delay
|
Prices in USD

Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Vlad Coric, M.D.
CEO
Dr. Vlad Coric, M.D.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
256
Head office
c/o Biohaven Pharmaceuticals, Inc
New Haven
United States
06510
mobile
+1 203 404-0410
letter
-

Key personnel

Salary
Ms. Julia P. Gregory
Independent Director
0.08m
Dr. Gregory Hugh Bailey, M.D.
Independent Director
0.06m
Mr. Robert J. Hugin
Independent Director
0.08m
Mr. Michael T. Heffernan, R.Ph.
Lead Independent Director
0.11m
Mr. John W. Childs
Independent Director
0.07m
Ms. Kimberly Gentile
Senior Vice President, Clinical Operations
0.49m
Dr. Vlad Coric, M.D.
Chief Executive Officer and Chairman of the Board
0.89m
Mr. Bruce Car
Chief Scientific Officer
0.52m
Mr. Kishan Mehta
Director
0.05m
Mr. George C. Clark
Chief Accounting Officer and Vice President
-
Mr. Matthew Buten
Chief Financial Officer
0.57m
Dr. Irina Antonijevic, M.D.,PhD
Independent Director
0.06m

Top 5 shareholders

No. of shares
Vanguard Group Inc. ( Junked)7,785,909
Vanguard Group Inc9,249,597
BlackRock Inc7,874,891
HHG PLC6,772,113
Stifel Financial Corp6,611,350

Director dealings

Action
30 Dec 2024-
02 Oct 2024-
02 Oct 2024-
24 Sep 2024-
18 Jul 2024-
17 Jun 2024-
30 May 2024-
13 May 2024-
13 May 2024-
30 Apr 2024-
30 Apr 2024-
30 Apr 2024-
30 Apr 2024-
30 Apr 2024-
30 Apr 2024-
30 Apr 2024-
24 Apr 2024-
22 Apr 2024-
22 Apr 2024-
22 Apr 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.